Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | IDE | P14735 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | HLCS | P50747 | 6/20 | 0.57 |
| ▸ | CA12 | O43570 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15123570 | 1.00 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15130513 | 0.91 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL903554 | 0.91 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL903561 | 0.88 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL30089573 | 0.88 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8071606 | 0.88 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4320917 | 0.88 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16141190 | 0.88 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1726093 | 0.87 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.87 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190268-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| WO-2012042123-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | SANOFI (FR) | 2012-04-05 | — | — | WO | disclosed |
| US-7078013-B2 | Pretargeting methods and compounds | ALETHEON PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040241172-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2004-12-02 | — | — | US | disclosed |
| US-6709652-B2 | RADIOACTIVE LABELING OF BIOTIN | NEORX CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030099640-A1 | Three-step pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-05-29 | — | — | US | disclosed |
| EP-0646019-B9 | Biotin-DOTA conjugates and their use in pretargeting methods | NEORX CORP (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6416738-B1 | ADMINISTERING TO A RECIPIENT A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND A MEMBER OF A LIGAND/ANTI-LIGAND BINDING PAIR, THEREAFTER ADMINISTERING TO THE RECIPIENT A CLEARING AGENT, ADMINISTERING SECOND CONJUGATE | NEORX CORPORATION | 2002-07-09 | — | — | US | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5578287-A | COMPOUNDS FOR MEDICAL DIAGNOSIS AND TARGETS AND ANTIBODIES | NEORX CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0736035-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0732943-A1 | THREE-STEP PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5541287-A | DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS | NEORX CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995015335-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995014493-A1 | THREE-STEP PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0646019-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993025240-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040241172-A1 | Pretargeting methods and compounds | HLCS, BTD, STRA6 | TDP1 3824/4885MEN1 723/4885ABL1 3654/4885 |
| US-20030099640-A1 | Three-step pretargeting methods and compounds | PAICS, KLK3, CD47 | TDP1 3450/4885MEN1 685/4885ABL1 555/4885 |
| US-20130190268-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | BTD, FGB, F13B | TDP1 4155/4885MEN1 3269/4885ABL1 4828/4885 |
| US-20030129191-A1 | Pretargeting methods and compounds | BTD, HLCS, STRA6 | TDP1 3339/4885MEN1 496/4885ABL1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.